Pioneers in Neuroscience

BIOGEN COVID-19 INFORMATION CENTER

Thank you to the many front-line workers and organizations working tirelessly to help in these difficult days. Please find updates on Biogen’s response to COVID-19 here.

Honoring our Intersectional Pride

At Biogen, we foster belonging in our intersectional communities where hate and discrimination have no place and where we work to reduce disparities.

WE STAND UNITED WITH THE AFRICAN AMERICAN AND BLACK COMMUNITY

Biogen is built on and committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Thank you to Biogen’s Director Lynn Schenk

We are thankful for the service of Lynn Schenk as a director of IDEC since 1995 and then a director of the merged Biogen company since 2004. Lynn will retire from the Biogen Board at the end of her current term, which expires at the 2020 annual meeting of stockholders.

6/16/20 4:06 PM EDT
Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
View all news
Our Stories

Future lawyer and chronic illness advocate, Lauren Work is on a mission to change the narrative of MS and improve health outcomes for underrepresented women.

2019 Year in Review

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen in our 2019 Year in Review.

Our focus

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.

REGARDING ADUCANUMAB

Biogen shared Phase 3 top-line data on our investigational therapy for early Alzheimer’s disease at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference. Watch the presentation.

For investor inquiries related to this announcement, please contact Biogen Investor Relations at IR@biogen.com.

On October 22, 2019, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease.

Learn more.

Follow us on social media